Cash Flow Statement

Acquisitions Amortization Amortization Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

AC Immune (ACIU) Gains from Investment Securities (2019)

AC Immune has reported Gains from Investment Securities over the past 1 years, most recently at $9.2 million for Q4 2019.

Quarterly Gains from Investment Securities changed N/A to $9.2 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $9.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$18767.5 for FY2025, N/A changed from the prior year.
Gains from Investment Securities was $9.2 million for Q4 2019 at AC Immune, up from $35903.1 in the prior quarter.
Over five years, Gains from Investment Securities peaked at $9.2 million in Q4 2019 and troughed at -$4.5 million in Q1 2019.